SELLING STOCKHOLDERS
This prospectus relates to the offer and sale from time to time by the selling stockholders, including their transferees, pledgees or donees or their respective successors of up to 5,942,722 shares of common stock, including up to 2,816,230 shares issuable upon the conversion of Series A 6% secured convertible promissory notes, 1,126,492 shares issuable upon the conversion of Series B 6% secured convertible promissory notes, and 2,000,000 shares issued or issuable upon the exercise of presently exercisable warrants, plus an indeterminate number of additional shares of common stock that may be issued from time to time upon conversion of the promissory notes or upon exercise of the warrants as a result of anti-dilution adjustments resulting from stock splits, stock dividends, or similar transactions.
All shares registered for resale in this prospectus are issuable (i) upon the conversion of the notes (including the potential total amount of interest payable under the notes through the maturity date) and (ii) upon the exercise of the warrants. The shares are being registered for resale in accordance with the Investor Rights Agreement executed in connection with the private placement transaction described below. The notes and warrants have fixed conversion and exercise prices, as applicable, and there are no substantive anti-dilution or reset provisions in either the notes or the warrants, and accordingly, no additional shares may be issued and sold under the applicable agreements governing the private placement transaction. The number of shares issuable upon conversion of the notes may be lower if the notes are converted prior to their maturity date, since less
interest will have accrued.
Background Regarding the Private Placement Transaction
The common stock offered herein is underlying securities sold in a private placement transaction under Rule 506 promulgated under the Securities Act of 1933, as amended, to the three accredited investors listed in the selling stockholder table below.
The Purchase Agreement
. On May 29, 2007, AXS-One entered into a Convertible Note and Warrant Purchase Agreement (the Purchase Agreement) pursuant to which it sold and issued an aggregate of $5,000,000 of convertible notes consisting of (i) $2,500,000 of Series A 6% Secured Convertible Promissory Notes due May 29, 2009 (the Series A Notes), and (ii) $2,500,000 of Series B 6% Secured Convertible Promissory Notes due May 29, 2009 (the Series B Notes and together with the Series A Notes, the Notes), together with warrants to purchase an aggregate of 2,000,000 shares of common stock of AXS-One at an exercise price of $0.01 per share (the Warrants). Net cash proceeds to AXS-One after transaction expenses were approximately $4.9 million, reflecting $100,000 paid for legal and other
filing fees and costs. In addition to the cash fees paid, there was a non-cash discount of $0.66 per warrant share, or $1,320,000 with respect to the 2,000,000 warrants issued, representing the difference between the market price of AXS-One common stock on the closing date of the financing ($0.67) and the exercise price of the Warrants ($0.01).
The Purchase Agreement provides that as long as any of the Notes remain outstanding, (a) BlueLine Partners, LLC shall have the right, from time to time, to designate one individual, in its sole discretion, to serve as a director of AXS-One (the Purchaser Director Designee), (b) AXS-One shall use its best efforts to cause the Purchaser Director Designee to be nominated and elected for service as director (the Purchaser Board Seat) promptly following the financing closing and at each meeting of AXS-One stockholders held for the purpose of electing directors and (c) if at any time, or from time to time, the Purchaser Board Seat is or becomes vacant for any reason prior to the next annual meeting of stockholders, AXS-One will use its best efforts to cause the vacancy to be filled with a Purchaser Director Designee. The right of BlueLine Partners, LLC set
forth in the Purchase Agreement is not transferable under any circumstances, whether by sale or assignment of notes or otherwise.
14
The Purchase Agreement contains negative covenants to the effect that unless approved in writing by the holders of a majority of the principal amount of the Notes then outstanding, AXS-One (a) shall not declare or pay any dividend or distribution with respect to its common stock, (b) shall not create and/or issue any classes of preferred stock, and (c) shall not incur any secured indebtedness senior to the Notes other than its current facility with Silicon Valley Bank or a comparable facility.
The Purchase Agreement also provides the Note holders with the right to participate in certain future securities offerings of AXS-One. During the period ending on May 29, 2009, the Note holders have the right to purchase their pro rata share of an aggregate of thirty percent (30%) of the securities being offered in the future offering on the same terms as that offered to the other investors in the offering.
The Notes.
The Series A Notes mature on May 29, 2009, are convertible into AXS-One common stock at a fixed conversion rate of $1.00 per share, bear interest of 6% per annum and are secured by substantially all the assets of AXS-One. The Series B Notes mature on May 29, 2009, are convertible into AXS-One common stock at a fixed conversion rate of $2.50 per share, bear interest of 6% per annum and are secured by substantially all the assets of AXS-One. Interest is compounded quarterly and payable at maturity; provided, that if the Note holders convert the notes into AXS-One common stock, any accrued interest amounts shall be converted into common stock. The Notes may be converted at the option of the Note holder at any time prior to maturity. The conversion prices of the Notes were at a premium to the market price per share of AXS-One
common stock on the closing date of the financing ($0.67).
The Warrants
. Each Note holder received a Warrant to purchase a number of shares of AXS-One common stock equal to 40% of the principal amount of notes purchased. Each Warrant has an exercise price of $0.01 per share and is exercisable at any time through May 29, 2014. There was a non-cash discount of $0.66 per warrant share, or $1,320,000 with respect to the 2,000,000 warrants issued, representing the difference between the market price of AXS-One common stock on the closing date of the financing ($0.67) and the exercise price of the Warrants ($0.01).
Other Transaction Agreements
. AXS-One and the investors entered into a Security Agreement pursuant to which BlueLine Capital Partners, LP, as agent for the Note holders, was granted a security interest in substantially all the assets of AXS-One to secure the payment obligations under the Notes. Pursuant to a Subordination Agreement, this security interest has been subordinated to the security interest of Silicon Valley Bank, AXS-Ones current senior lender. The parties also entered into an Investor Rights Agreement, pursuant to which AXS-One agreed to file this registration statement to allow the selling stockholders to sell any AXS-One common stock issued upon conversion of the Notes or upon exercise of the Warrants.
Payments in Connection with the Private Placement
. The only payment in connection with the transaction that AXS-One is required to make to the selling stockholders is payment of principal and interest on the Notes. Interest on the outstanding principal balance of the Notes accrues at a rate of six percent (6.00%) per annum, compounded quarterly, to be paid at maturity on May 29, 2009 (unless the obligation to pay has been accelerated by a sale of AXS-One or prepayment of the Notes); provided, that in the case of the conversion of the Notes at the option of the investors into common stock interest is payable in the form of shares of AXS-One common stock. The total outstanding principal of all Series A Notes and Series B Notes is $2,500,000 each, for an aggregate outstanding principal of all Notes of $5,000,000. If there has been no
acceleration of the obligation to pay, on May 29, 2009, the total accumulated aggregate interest on the Series A Notes and Series B Notes will be $316,231 each. Upon conversion of the Series A Notes on May 29, 2009, AXS-One will distribute to the investors 316,230 shares of its common stock, and upon conversion of the Series B Notes on May 29, 2009, AXS-One will distribute to the investors 126,492 shares of its common stock, for a total distribution of 442,722 shares of
15
common stock, as payment of this interest. If the notes are converted prior to maturity, the accrued interest would be lower and fewer shares would be issued as payment of interest. There were no finders or placement agents fees related to this transaction, and there are no other payments that AXS-One is required to make to the selling shareholders, including liquidated damages and any other payments or potential payments. As described herein, BlueLine Capital is entitled to appoint one member of the Board of Directors of AXS-One and that person is compensated for Board service in the same manner as other non-employee directors.
Impact and Tabular Analysis of the Private Placement Transaction
Financial Statement and Capital Structure Impact
Net cash proceeds to AXS-One after transaction expenses were approximately $4.9 million, reflecting $100,000 paid for legal and other filing fees and costs. In addition to the cash expenses paid, there was a non-cash expense relating to the discount of $0.66 per warrant share, or $1,320,000, with respect to the 2,000,000 warrants issued, representing the difference between the market price of AXS-One common stock on the closing date of the financing ($0.67) and the exercise price of the Warrants ($0.01). For financial statement purposes, the non-cash expense is amortized as interest expense monthly over the two year term of the notes. This non-cash expense, when added to the cash expenses, resulted in aggregate expenses related to the transaction of $1,420,000.
The potential conversion of the Notes (including accrued interest to maturity) and the warrants would result in the aggregate issuance of up to 5,942,722 shares of our common stock.
Tabular Analysis
The following table shows the value of the Notes had they been converted into our common stock on May 29, 2007 (the date of initial issuance) based upon the market price of AXS-One common stock on that date. We note that the ultimate profit or loss to the investors related to the Notes is speculative and dependent upon the timing of any conversion and the future price per share of our common stock.
|
|
Shares
|
|
Market
Price on
5/29/07
|
|
Conversion
Price
|
|
Profit
Per Share
|
|
Total
Profit
|
|
Principal
Conversion
Shares
|
|
Market
Price of
Shares
|
|
Total
Discount
To Market
|
|
Series A Convertible Notes
|
|
2,500,000
|
|
$
|
0.67
|
|
$
|
1.00
|
|
$
|
(0.33
|
)
|
$
|
(825,000
|
)
|
2,500,000
|
|
$
|
1,675,000
|
|
|
|
Series B Convertible Notes
|
|
1,000,000
|
|
$
|
0.67
|
|
$
|
2.50
|
|
$
|
(1.83
|
)
|
$
|
(1,830,000
|
)
|
1,000,000
|
|
$
|
670,000
|
|
|
|
Total
|
|
3,500,000
|
|
|
|
|
|
|
|
|
|
|
$
|
(2,655,000
|
)
|
3,500,000
|
|
$
|
2,345,000
|
|
|
|
The following table shows the value of the warrants had they been exercised for shares of our common stock on May 29, 2007 (the date of initial issuance) based upon the market price of AXS-One common stock on that date. We note that the ultimate profit or loss to the investors related to the exercise of the warrants is speculative and dependent upon the timing of any exercise and the future price per share of our common stock.
16
|
|
Shares
|
|
Market
Price on
5/29/07
|
|
Exercise
Price
|
|
Profit
Per Share
|
|
Total
Profit
|
|
Total
Possible
Shares
|
|
Market
Price of
Shares
|
|
Total
Possible
Discount
To
Market
|
|
Warrants
|
|
2,000,000
|
|
|
$0.67
|
|
|
$0.01
|
|
|
$0.66
|
|
|
$1,320,000
|
|
2,000,000
|
|
|
$1,340,000
|
|
|
$1,320,000
|
|
Total
|
|
2,000,000
|
|
|
|
|
|
|
|
|
|
|
|
$1,320,000
|
|
2,000,000
|
|
|
$1,340,000
|
|
|
$1,320,000
|
|
The following table shows the aggregate value of the Notes and warrants had they been converted into or exercised for shares of our common stock on May 29, 2007 (the date of initial issuance) based upon the market price of AXS-One common stock on that date. We note that the ultimate profit or loss to the investors related to the conversion of the Notes and the exercise of the warrants is speculative and dependent upon the timing of any conversion or exercise and the future price per share of our common stock.
Total Profit of selling stockholders resulting from Notes conversion and warrant exercise at May 29, 2007:
|
Note conversion
|
|
|
$(2,655,000
|
)
|
Warrant exercise
|
|
|
$1,320,000
|
|
Total
|
|
|
$(1,335,000
|
)
|
Total discount to market of the conversion shares
|
|
|
0
|
|
The following provides a tabular analysis of the cash and non-cash costs of the financing transaction, including as a percentage of the gross transaction proceeds.
Transaction Cost Details
|
|
|
|
|
|
|
|
|
|
% of Total
|
|
Gross Proceeds of Transaction
|
|
|
$5,000,000
|
|
100.0%
|
|
Payments to be made by AXS-One Represents legal and accounting costs
|
|
|
$100,000
|
|
2.0%
|
|
Net Cash Proceeds
|
|
|
$4,900,000
|
|
98.0%
|
|
Non-Cash charge relating to warrant discount
|
|
|
$1,320,000
|
|
26.4%
|
|
Proceeds after all expenses
|
|
|
$3,580,000
|
|
71.6%
|
|
17
Selling Stockholder Information
None of the selling stockholders nor any of their affiliates, officers, directors or principal equity holders has held any position or office or has had any material relationship with us within the past three years, except in connection with the private placement transaction described above. In connection with our sale and issuance of the Notes and Warrants, we agreed to grant BlueLine Capital, LLC the right to designate one individual to serve on our Board of Directors while the notes are outstanding. Effective May 29, 2007, we increased the size of our Board of Directors to nine members and in accordance with the terms of Purchase Agreement filled the vacancy created thereby by appointing Timothy P. Bacci to our Board. Mr. Bacci is a Managing Director of BlueLine Partners, an affiliate of BlueLine Capital Partners, LP and BlueLine Capital Partners II. LP, which are each
selling stockholders hereunder.
There have been no prior securities transactions between AXS-One (or any of its predecessors) and the selling stockholders, any affiliates of the selling stockholders, or any person with whom any selling stockholder has a contractual relationship regarding the transaction (or any predecessors of those persons).
The selling stockholders listed in the table below may have sold or transferred, in transactions exempt from the registration requirements of the Securities Act of 1933, as amended, some or all of their common stock since the date as of which the information in the table is presented. Information about the selling stockholders may change over time. Any changed information will be set forth in an amendment to the registration statement or supplement to this prospectus, as required by law. None of the selling stockholders are broker-dealers or affiliated with a broker-dealer.
The following table contains information furnished to us by the selling stockholders, as of September 26, 2007, with respect to the selling stockholders and the common stock beneficially owned by each selling stockholder that may be offered under this prospectus. We prepared this table based on information supplied to us by the selling stockholders named in the table and have not sought to verify such information.
Name
|
|
Number of
shares of
common
stock
beneficially
owned prior
to the offering
|
|
Percentage of
common
stock
outstanding
|
|
Number of
shares of
common
stock that
may be sold
hereby
|
|
Number of
shares of
common
stock
beneficially
owned after
the offering
(1)
|
|
Percentage of
common
stock
outstanding
(1)
|
|
BlueLine Capital Partners, LP
|
|
5,533,025
|
(2)
|
|
13.6
|
%
|
|
2,971,361
|
(3)
|
|
2,233,025
|
(4)
|
|
5.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BlueLine Capital Partners II, LP
|
|
5,533,025
|
(2)
|
|
13.6
|
%
|
|
594,272
|
(5)
|
|
2,233,025
|
(4)
|
|
5.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jurika Family Trust U/A
3/17/1989
|
|
5,225,066
|
(6)
|
|
13.4
|
%
|
|
2,377,089
|
(7)
|
|
3,025,066
|
(8)
|
|
7.8
|
%
|
|
______________
18
(1)
|
Assumes the conversion of all notes and the exercise of all warrants offered by this prospectus by the applicable selling stockholder and no other purchases or sales of our common stock by the selling stockholder.
|
(2)
|
Consists of: (i) 1,899,815 shares of common stock held by BlueLine Capital Partners, LP; (ii) 150,350 shares of common stock held by BlueLine Capital Partners II, LP; (iii) 142,860 shares of common stock held by BlueLine Capital Partners III, LP; (iv) 40,000 shares of restricted common stock held by Timothy P. Bacci; (v) 1,250,000 shares of common stock issuable upon conversion of principal of Series A 6% Secured Convertible Promissory Notes held by BlueLine Capital Partners, LP; (vi) 500,000 shares of common stock issuable upon conversion of principal of Series B 6% Secured Convertible Promissory Notes held by BlueLine Capital Partners, LP; (vii) 1,000,000 shares of common stock issuable upon exercise of warrants held by BlueLine Capital Partners, LP; (viii) 250,000 shares of common stock issuable upon conversion of Series A 6% Secured
Convertible Promissory Notes held by BlueLine Capital Partners II, LP; (ix) 100,000 shares of common stock issuable upon conversion of Series B 6% Secured Convertible Promissory Notes held by BlueLine Capital Partners II, LP; and (x) 200,000 shares of common stock issuable upon exercise of warrants held by BlueLine Capital Partners II, LP. Timothy P. Bacci, a managing director of BlueLine Partners may be deemed to beneficially own the foregoing shares. The address of BlueLine Capital Partners, LP and BlueLine Capital Partners II, LP is 402 Railroad Avenue, Suite 201, Danville, CA 94526.
|
(3) Consists of: (i) 1,250,000 shares of common stock issuable upon conversion of principal of Series A 6% Secured Convertible Promissory Notes held by BlueLine Capital Partners, LP; (ii) 500,000 shares of common stock issuable upon conversion of principal of Series B 6% Secured Convertible Promissory Notes held by BlueLine Capital Partners, LP; (iii) 158,115 shares of common stock issuable upon conversion of interest on Series A 6% Secured Convertible Promissory Notes held by BlueLine Capital Partners, LP; (iv) 63,246 shares of common stock issuable upon conversion of interest on Series B 6% Secured Convertible Promissory Notes held by BlueLine Capital Partners, LP and (v) 1,000,000 shares of common stock issuable upon exercise of warrants held by BlueLine Capital Partners, LP.
(4) Consists of: (i) 1,899,815 shares of common stock held by BlueLine Capital Partners, LP; (ii) 150,350 shares of common stock held by BlueLine Capital Partners II, LP; (iii) 142,860 shares of common stock held by BlueLine Capital Partners III, LP; and (iv) 40,000 shares of restricted common stock held by Timothy P. Bacci. Assumes that all shares of common stock issuable as described in Notes (3) and (5) will sold.
(5) Consists of: (i) 250,000 shares of common stock issuable upon conversion of Series A 6% Secured Convertible Promissory Notes held by BlueLine Capital Partners II, LP; (ii) 100,000 shares of common stock issuable upon conversion of Series B 6% Secured Convertible Promissory Notes held by BlueLine Capital Partners II, LP; (iii) 31,623 shares of common stock issuable upon conversion of interest on Series A 6% Secured Convertible Promissory Notes held by BlueLine Capital Partners II, LP; (iv) 12,649 shares of common stock issuable upon conversion of interest on Series B 6% Secured Convertible Promissory Notes held by BlueLine Capital Partners II, LP; and (v) 200,000 shares of common stock issuable upon exercise of warrants held by BlueLine Capital Partners II, LP.
(6)
|
Consists of: (i) 3,222,700 shares of common stock held by Jurika Family Trust U/A 3/17/1989 (including 800,000 shares of common stock issued upon exercise of warrants held by Jurika Family Trust U/A 3/17/1989 issued in the May 2007 private placement transaction); (ii) 498,900 shares of common stock held by William K. Jurika IRA; (iii) 2,700 shares of common stock held by Michelle Jurika IRA; (iv) 100,766 shares of common stock issuable upon exercise of warrants held by Jurika Family Trust U/A 3/17/1989; (v) 1,000,000 shares of common stock issuable upon conversion of Series A 6% Secured Convertible Promissory Notes held by Jurika Family Trust U/A 3/17/1989; and (vi) 400,000 shares of common stock issuable upon conversion of Series B 6% Secured Convertible Promissory Notes held by Jurika Family Trust U/A 3/17/1989. William K. Jurika has sole voting and
dispositive power over all of the foregoing shares. The address of Jurika Family Trust U/A 3/17/1989 is 42 Glen Alpine Road, Piedmont, CA 94611.
|
19
(7)
|
Consists of: (i) 1,000,000 shares of common stock issuable upon conversion of Series A 6% Secured Convertible Promissory Notes held by Jurika Family Trust U/A 3/17/1989; (ii) 400,000 shares of common stock issuable upon conversion of principal of Series B 6% Secured Convertible Promissory Notes held by Jurika Family Trust U/A 3/17/1989; (iii) 800,000 shares of common stock issued upon exercise of warrants held by Jurika Family Trust U/A 3/17/1989; (iv) 126,492 shares of common stock issuable upon conversion of interest payable on Series A 6% Secured Convertible Promissory Notes held by Jurika Family Trust U/A 3/17/1989; and (v) 50,597 shares of common stock issuable upon conversion of interest payable on Series B 6% Secured Convertible Promissory Notes held by Jurika Family Trust U/A 3/17/1989.
|
(8)
|
Consists of: (i) 2,422,700 shares of common stock held by Jurika Family Trust U/A 3/17/1989; (ii) 498,900 shares of common stock held by William K. Jurika IRA; (iii) 2,700 shares of common stock held by Michelle Jurika IRA; and (iv) 100,766 shares of common stock issuable upon exercise of warrants held by Jurika Family Trust U/A 3/17/1989.
|
PLAN OF DISTRIBUTION
We are registering the shares of common stock on behalf of the selling security holders. Sales of shares may be made by selling security holders, including their respective donees, transferees, pledgees or other successors-in-interest directly to purchasers or to or through underwriters, broker-dealers or through agents. Sales may be made from time to time on the American Stock Exchange, any other exchange or market upon which our shares may trade in the future, in the over-the-counter market or otherwise, at market prices prevailing at the time of sale, at prices related to market prices, or at negotiated or fixed prices. The shares may be sold by one or more of, or a combination of, the following:
a block trade in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction (including crosses in which the same broker acts as agent for both sides of the transaction);
|
|
purchases by a broker-dealer as principal and resale by such broker-dealer, including resales for its account, pursuant to this prospectus;
|
|
|
ordinary brokerage transactions and transactions in which the broker solicits purchases;
|
|
|
through options, swaps or derivatives;
|
|
|
in privately negotiated transactions;
|
|
|
in making short sales or in transactions to cover short sales; and
|
|
|
put or call option transactions relating to the shares.
|
The selling security holders may effect these transactions by selling shares directly to purchasers or to or through broker-dealers, which may act as agents or principals. These broker-dealers may receive compensation in the form of discounts, concessions or commissions from the selling security holders and/or the purchasers of shares for whom such broker-dealers may act as agents or to whom they sell as principals, or both (which compensation as to a particular broker-dealer might be in excess of customary commissions). The selling security holders have advised us that they have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale of their securities.
20
The selling security holders may enter into hedging transactions with broker-dealers or other
financial institutions. In connection with those transactions, the broker-dealers or other financial institutions may engage in short sales of the shares or of securities convertible into or exchangeable for the shares in the course of hedging positions they assume with the selling security holders. The selling security holders may also enter into options or other transactions with broker-dealers or other financial institutions which require the delivery of shares offered by this prospectus to those broker-dealers or other financial institutions. The broker-dealer or other financial institution may then resell the shares pursuant to this prospectus (as amended or supplemented, if required by applicable law, to reflect those transactions).
The selling security holders and any broker-dealers that act in connection with the sale of shares may be deemed to be underwriters within the meaning of Section 2(11) of the Securities Act of 1933, and any commissions received by broker-dealers or any profit on the resale of the shares sold by them while acting as principals may be deemed to be underwriting discounts or commissions under the Securities Act. The selling security holders may agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of the shares against liabilities, including liabilities arising under the Securities Act. We have agreed to indemnify each of the selling security holders and each selling security holder has agreed, severally and not jointly, to indemnify us against some liabilities in connection with the offering of the shares, including
liabilities arising under the Securities Act.
The selling security holders will be subject to the prospectus delivery requirements of the Securities Act. We have informed the selling security holders that the anti-manipulative provisions of Regulation M promulgated under the Securities Exchange Act of 1934 may apply to their sales in the market.
Selling security holders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided they meet the criteria and conform to the requirements of Rule 144.
Upon being notified by a selling security holder that a material arrangement has been entered into with a broker-dealer for the sale of shares through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, we will file a supplement to this prospectus, if required pursuant to Rule 424(b) under the Securities Act, disclosing:
|
|
the name of each such selling security holder and of the participating broker-dealer(s);
|
|
|
the number of shares involved;
|
|
|
the initial price at which the shares were sold;
|
|
|
the commissions paid or discounts or concessions allowed to the broker-dealer(s), where applicable;
|
|
|
that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus; and
|
|
|
other facts material to the transactions.
|
In addition, if required under applicable law or the rules or regulations of the Commission, we will file a supplement to this prospectus when a selling security holder notifies us that a donee or pledgee intends to sell more than 500 shares of common stock.
21
We are paying all expenses and fees customarily paid by the issuer in connection with the registration of the shares. The selling security holders will bear all brokerage or underwriting discounts or commissions paid to broker-dealers in connection with the sale of the shares.
EXPERTS
The consolidated financial statements and the consolidated Schedule II Valuation and Qualifying Accounts of AXS-One Inc. and subsidiaries as of December 31, 2006, and for the year then ended, have been incorporated by reference herein and in the registration statement in reliance upon the reports of Amper, Politziner & Mattia, P.C., an independent registered public accounting firm, upon the authority of said firm as experts in accounting and auditing.
The consolidated balance sheet of AXS-One Inc. and subsidiaries as of December 31, 2005, and the related consolidated statements of operations, comprehensive income (loss), stockholders deficit and cash flows for the years ended December 31, 2005 and 2004, before the effects of the adjustments to retrospectively report the discontinued operations described in Note 2 to the 2006 consolidated financial statements, (not separately included or incorporated by reference herein) and the related consolidated financial statement schedule for the years ended December 31, 2005 and 2004, have been audited by KPMG LLP. The adjustments to the consolidated financial statements to retrospectively report the discontinued operations described in Note 2 to the 2006 consolidated financial statements have been audited by Amper, Politziner & Mattia, P.C. The consolidated financial
statements and schedule of AXS-One Inc. and subsidiaries as of December 31, 2005 and for the years ended December 31, 2005 and 2004 incorporated herein and in the registration statement by reference to the Annual Report on Form 10-K for the year ended December 31, 2006, have been incorporated by reference herein and in the registration statement in reliance upon the reports of (i) KPMG LLP, independent registered public accounting firm, solely with respect to the consolidated financial statements before the effects of the adjustments to retrospectively report the discontinued operations described in Note 2, and the consolidated financial statement schedule and (ii) Amper, Politziner & Mattia, P.C., solely with respect to the adjustments to the consolidated financial statements to retrospectively report the discontinued operations described in Note 2, upon the authority of said firms as experts in accounting and auditing.